AZD-8055
AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. AZD-8055 inhibits both mTORC1 and mTORC2[1].
Product Specifications
CAS Number
1009298-09-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Autophagy; mTOR
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/AZD-8055.html
Purity
99.60
Solubility
DMSO : 33.33 mg/mL (ultrasonic)
Smiles
OCC1=CC(C2=NC3=NC(N4CCOC[C@@H]4C)=NC(N5[C@@H](C)COCC5)=C3C=C2)=CC=C1OC
Molecular Formula
C25H31N5O4
Molecular Weight
465.54
Precautions
H302, H315, H319, H335
References & Citations
[1]Chresta CM, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res, 2010, 70 (1), 288-298.|[2]You W, et al. Inhibition of mammalian target of rapamycin attenuates early brain injury through modulating microglial polarization after experimental subarachnoid hemorrhage in rats. J Neurol Sci. 2016 Aug 15;367:224-31.|[3]Kawata T, et al. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia. Cancer Sci. 2017 Oct 27.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
MTOR; mTORC1; mTORC2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
